Investor Relations
Investors
View the Latest Stock Trading Information
Review BioStem’s latest trading data, historical quotes, volume, and key statistics.
News
Sign Up with Email Alerts Today.
Get news, filings, and events directly in your inbox with our automated Email Alerts
Symbol
OTC : BSEMPrice
$Volume
Change
Investor Relations
BioStem Technologies
Press Releases
Latest News
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg UlcersStudy comparing BioStem’s proprietary amnion chorion allograft versus the...
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 MillionPOMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) --BioStem Technologies, Inc.(OTC: BSEM)...
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting...
Quarterly
Results
Stock
Information
Presentations
& Brochures
Upcoming
Events



